EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

In vivo bone marrow microenvironment siRNA delivery using lipid–polymer nanoparticles for multiple myeloma therapy

Pedro P G Guimarães iD, Christian G Figueroa-Espada iD, Rachel S Riley, Ningqiang Gong, Lulu Xue iD, Tomasz Sewastianik iD, Peter S Dennis, Claudia Loebel, Amanda Chung, Sarah J Shepherd, Rebecca M Haley iD, Alex G Hamilton iD und 6 weitere

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2215711120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Pedro P G Guimarães und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 52-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM), a hematologic malignancy that preferentially colonizes the bone marrow, remains incurable with a survival rate of 3 to 6 mo for those with advanced disease despite great efforts to develop effective therapies. Thus, there is an urgent clinical need for innovative and more effective MM therapeutics. Insights suggest that endothelial cells within the bone marrow microenvironment play a critical role. Specifically, cyclophilin A (CyPA), a homing factor secreted by bone marrow endothelial cells (BMECs), is critical to MM homing, progression, survival, and chemotherapeutic resistance. Thus, inhibition of CyPA provides a potential strategy to simultaneously inhibit MM progression and sensitize MM to chemotherapeutics, improving therapeutic response. However, inhibiting factors from the bone marrow endothelium remains challenging due to delivery barriers. Here, we utilize both RNA interference (RNAi) and lipid–polymer nanoparticles to engineer a potential MM therapy, which targets CyPA within blood vessels of the bone marrow. We used combinatorial chemistry and high-throughput in vivo screening methods to engineer a nanoparticle platform for small interfering RNA (siRNA) delivery to bone marrow endothelium. We demonstrate that our strategy inhibits CyPA in BMECs, preventing MM cell extravasation in vitro. Finally, we show that siRNA-based silencing of CyPA in a murine xenograft model of MM, either alone or in combination with the Food and Drug Administration (FDA)-approved MM therapeutic bortezomib, reduces tumor burden and extends survival. This nanoparticle platform may provide a broadly enabling technology to deliver nucleic acid therapeutics to other malignancies that home to bone marrow.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaUnited StatesHumansAnimalsMiceBone MarrowRNA, Small InterferingEndothelial CellsCyclophilin ALipidsTumor Microenvironment

Stichwörter der Autor:innen

RNA therapeuticsdrug deliverynanomedicine

Substanzen

RNA, Small InterferingCyclophilin ALipids

Autor:innen und Institutionen

  • Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104.
  • Department of Physiology and Biophysics, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG 31270-901, Brazil.
  • Department of Biomedical Engineering, Rowan University, Glassboro, NJ 08028.
  • Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
  • Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw 02776, Poland.
  • Department of Materials Science & Engineering, University of Michigan, North Campus Research Complex, Ann Arbor, MI 48109.

ORCID-Profile: Pedro P G Guimarães, Christian G Figueroa-Espada, Lulu Xue, Tomasz Sewastianik, Rebecca M Haley, Alex G Hamilton, Rakan El-Mayta, Robert Langer, Ruben D Carrasco, Michael J Mitchell

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIDDK NIH HHS
  • HHS | National Institutes of Health

Zitieren

APA

Guimarães, P. P. G., Figueroa-Espada, C. G., Riley, R. S., Gong, N., Xue, L., Sewastianik, T., Dennis, P. S., Loebel, C., Chung, A., Shepherd, S. J., Haley, R. M., Hamilton, A. G., El-Mayta, R., Wang, K., Langer, R., Anderson, D. G., Carrasco, R. D., & Mitchell, M. J. (2023). In vivo bone marrow microenvironment siRNA delivery using lipid–polymer nanoparticles for multiple myeloma therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2215711120

Vancouver

Guimarães PPG, Figueroa-Espada CG, Riley RS, Gong N, Xue L, Sewastianik T, et al. In vivo bone marrow microenvironment siRNA delivery using lipid–polymer nanoparticles for multiple myeloma therapy. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2215711120

BibTeX
@article{Guimares2023,
  author = {Guimarães, Pedro P G and Figueroa-Espada, Christian G and Riley, Rachel S and Gong, Ningqiang and Xue, Lulu and Sewastianik, Tomasz and Dennis, Peter S and Loebel, Claudia and Chung, Amanda and Shepherd, Sarah J and Haley, Rebecca M and Hamilton, Alex G and El-Mayta, Rakan and Wang, Karin and Langer, Robert and Anderson, Daniel G and Carrasco, Ruben D and Mitchell, Michael J},
  title = {In vivo bone marrow microenvironment siRNA delivery using lipid–polymer nanoparticles for multiple myeloma therapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2215711120}
}
Kostenlos starten →